Olympus Launches CT-Based AI Software for Emphysema Screening
Through AI assessment of chest CT scans, the SeleCT Screening may help identify candidates for bronchoscopic lung volume reduction to improve lung function.
A new computed tomography (CT)-based artificial intelligence (AI) software may facilitate more timely detection of emphysema.
The SeleCT™ Screening software utilizes AI to help detect severe emphysema in patients, who may be viable candidates for minimally invasive bronchoscopic lung volume reduction (BLVR), according to Olympus, the developer of the SeleCT Screening software.
For people with emphysema, the AI-powered SeleCT Screening software could help identify potential candidates for minimally invasive bronchoscopic lung volume reduction (BLVR), according to Olympus, the developer of the software. (Image courtesy of Adobe Stock.)
Noting that emphysema has been diagnosed in more than three million people in the United States and that up to 80 percent of patients with chronic obstructive pulmonary disease (COPD) are underdiagnosed, Olympus said the SeleCT Screening software can lead to improved detection and timely intervention to bolster lung function.
"Emphysema can have a debilitating effect on a person's life. Bronchoscopic lung volume reduction is a way to help those dealing with the disease to reclaim some of the freedoms they may have lost," said Kyle Hogarth, M.D., a professor medicine and director of bronchoscopy at the University of Chicago. "Technology like SeleCT Screening is an effective way to more quickly identify those who could most benefit from treatment and experience an improved quality of life."
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
